Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial

Cancer Biology & Therapy
Gaetano FacchiniRosario V Iaffaioli

Abstract

Docetaxel (DTX) and zoledronic acid (ZOL) are effective in patients with hormone resistant prostate cancer (HRPC) with bone metastases. A phase I clinical trial of metronomic administration of Zoledronic Acid AN d TaxoterE combination (ZANTE trial) in 2 different sequences was conducted in HRPC. The maximum tolerated dose was not achieved with sequence A. Two patients at third level of sequence B developed dose limiting toxicity. A disease control was obtained in six out of nine patients treated with sequence A, where a decrease of biological markers and PSA were also observed. No evidence of anti-tumor activity was observed in patients treated with sequence B. Twenty-two patients enrolled into the study (median age: 73 years; range: 43-80) received one of three escalated doses of DTX (30, 40 and 50 mg/m(2)) in combination with a fixed dose of ZOL (2 mg), both administered every 14 days in two different sequences: DTX at the day 1 followed by ZOL at the day 2 (sequence A) or the reverse (sequence B). Patients were evaluated for adverse events and serum IL-8, MMP-2 and MMP-9 were evaluated prior and after therapy with the two sequences of administration of DTX and ZOL. The bi-weekly combination of DTX (50 mg/m(2)) followed by ZO...Continue Reading

Citations

Aug 31, 2011·Prostate Cancer and Prostatic Diseases·H K KoulR B Meacham
Oct 10, 2012·Anti-cancer Drugs·Giuseppe Di LorenzoSabino De Placido
Dec 24, 2010·Breast Cancer Research : BCR·Ingunn Holen, Robert E Coleman
Nov 3, 2011·Future Oncology·Stephen MetcalfRichard Morgan
Mar 23, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Joaquim Bosch-BarreraCatherine Van Poznak
Apr 17, 2013·Expert Opinion on Investigational Drugs·Michel D WissingHans Gelderblom
Mar 5, 2011·Critical Reviews in Oncology/hematology·Luis CostaAllan Lipton
Jan 3, 2013·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Ana Carolina Uchoa VasconcelosKaren Cherubini
Jan 21, 2012·Journal of Cellular and Molecular Medicine·Lavinia InsalacoAntonio Russo
Jun 4, 2013·Investigational New Drugs·Annabelle ChowUrban Emmenegger
Nov 29, 2014·Journal of Cancer Research and Clinical Oncology·Ke-Wang LuoClara Bik-San Lau
Aug 10, 2013·Trends in Pharmacological Sciences·Subash C GuptaBharat B Aggarwal
Mar 31, 2015·BioMed Research International·Guohua HuangYu-Dong Cai
Feb 8, 2019·Expert Opinion on Pharmacotherapy·Antoine Finianos, Jeanny B Aragon-Ching
Apr 27, 2017·Oncotarget·Daniela VanacoreGaetano Facchini
Aug 10, 2011·Current Opinion in Supportive and Palliative Care·James R Berenson
Apr 30, 2019·American Journal of Therapeutics·Marissa B SerafinRosmari Hörner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.